While 1 in 3 trials on cancer treatment excluded patients with cardiovascular disease, definitions and reasoning for exclusion were not well documented.
Subgroup analyses of outcomes following development of disease refractory to a CD38-targeting agent suggested that carfilzomib + an alkylator have some efficacy.
The authors of this statement on human germline editing distinguished “genetic correction” from “genetic enhancement.”
Prophylactic brain irradiation was associated with a significant improvement in disease-free survival and a significant reduction in likelihood of developing brain metastases.
The Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab; Genentech), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Poor prognostic factors for patients with EMZL include age greater than 70 years, advanced Ann Arbor stage, and elevated lactate dehydrogenase (LDH)
Septic shock is a leading cause of death in chemotherapy-treated patients with neutropenia, and updated guidelines for managing sepsis in this setting were recently published in Annals of Hematology.
Whole-genome sequencing of tumor specimens from patients with chemoresistant SCLC showed evidence of the deletion of multiple tumor suppressor genes.
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.